New combo therapy aims to ease tough schizophrenia symptoms
NCT ID NCT06574360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a second drug that boosts NMDA receptors to a sigma-1 receptor agonist can better reduce schizophrenia symptoms than the sigma-1 drug alone. About 90 adults with schizophrenia who did not improve on at least two antipsychotics will take the combination for 8 weeks. The main goal is to see if their overall symptoms, measured by a standard scale, get better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Psychiatry, China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video call strengthen families facing schizophrenia?
- Virtual family therapy may tame schizophrenia symptoms — a trial investigates
- Could a Once-Every-Few-Weeks shot replace daily pills for schizophrenia?
- Can a tailored self-management program improve health outcomes for those with serious mental illness?
- PET scans reveal how antipsychotics target key brain receptors in schizophrenia
- Immune clues in schizophrenia: could inflammation subtypes guide treatment?